Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy

NCT01828346 is registered in ClinicalTrials.gov with TetraLogic Pharmaceuticals as lead sponsor.

NCT NCT01828346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01828346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Lead sponsor
TetraLogic Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2013
Completion date
November 30, 2015
Enrollment
21 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome